No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial-Reference-Cited by-同舟云学术

No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial

Published:2019-02-11 Issue:3 Volume:6 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Li Jonathan Z¹^ORCID,Sax Paul E¹,Marconi Vincent C²,Fajnzylber Jesse¹,Berzins Baiba³,Nyaku Amesika N⁴^ORCID,Fichtenbaum Carl J⁵,Wilkin Timothy⁶,Benson Constance A⁷,Koletar Susan L⁸,Lorenzo-Redondo Ramon³,Taiwo Babafemi O³

Affiliation:

1. Division of Infectious Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachussetts

2. Division of Infectious Diseases, Emory University School of Medicine and Rollins School of Public Health, Atlanta, Georgia

3. Division of Infectious Diseases, Northwestern University, Chicago, Illinois

4. Division of Infectious Diseases, Rutgers University, Newark, New Jersey

5. Division of Infectious Diseases, University of Cincinnati, Cincinnati, Ohio

6. Division of Infectious Diseases, Weill Cornell Medicine, New York, New York

7. Division of Infectious Diseases, University of California, San Diego, California

8. Division of Infectious Diseases, Ohio State University, Columbus, Ohio

Abstract

Abstract In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to increased residual viremia. At entry, levels of residual viremia did not differ significantly between arms (DTG+3TC vs 3-drug ART: mean, 5.0 vs 4.2 HIV-1 RNA copies/mL; P = .64). After randomization, no significant between-group differences were found at either week 24 or 48. These results show no evidence for increased viral replication on DTG+3TC and support its further investigation as a dual ART strategy.

Funder

Emory CFAR

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/article-pdf/6/3/ofz056/33590441/ofz056.pdf

Reference25 articles.

1. Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial;Taiwo;Clin Infect Dis,2018

2. Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia;Campillo-Gimenez;AIDS,2015

3. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial;Blanco;J Antimicrob Chemother,2018